Psychiatric aspects of neurological diseases Flashcards
Usual age of onset of symptoms of MS
20-40
Lifetime risk of MS in the UK
1 in 8000
Male:Female ratio of MS
1:2
Percentage of patients with MS who show a primary progressive course
5-10%
Percentage of patients with MS who show a relapsing remitting course
20-30%
Percentage of patients with MS who show a relapsing remitting course initially and then a secondary progressive phase
60%
Lifetime prevalence of depression among patients with MS
40-50%
MS related drugs which can cause depression
Steroids (most likely)
Baclofen
Dantrolene
Tizanidine
Beta interferon - controversial link (Interferon alpha which is not used for MS is clearly linked to depression)
Percentage chance of triggering a relapse if ECT is used for depression in MS
20%
Percentage of patients with MS with suicidal ideation
30%
Percentage of patients given steroids who develop mild/moderate mania
33%
Area of brain where lesions are often seen in patients with MS who become psychotic
Bilateral temporal horn areas
Medication which has been shown to improve cognitive function in patients with MS related cognitive impairment
Donepezil
Most common psychiatric symptom following stroke
Depression
Brain areas of stroke most commonly associated with post-stroke depression
Left basal ganglia
Left frontal lobe
Antidepressants with good evidence for post-stroke depression
Fluoxetine
Citalopram
Percentage of patients with epilepsy who have depression
30-50%
Percentage of patients with epilepsy who have panic disorder
20%
Percentage of patients with epilepsy who have psychosis
3-7%
Type of epilepsy most associated with depression
Temporal lobe epilepsy
Anti-epileptic drug associated with developing psychosis
Vigabatrin
Features consistent with pseudo-seizures rather than seizures
More likely to happen in the daytime or with others present
Less likely to sustain injuries
Side to side head movements
Prolonged seizures
Eyes kept tightly shut
Maintaining of body tone
Rapid recovery post-seizure
Ability to recall events
Crying or emotional displays
Normal post-ictal lactate and prolactin
Percentage of patients with Parkinson’s disease who have depression
40-50%
Percentage of patients with Parkinson’s disease who have euphoria
10%
Percentage of patients with Parkinson’s disease who have anxiety
50-65%
Percentage of patients with Parkinson’s disease who have psychosis (including drug related)
40%
Percentage of patients with Parkinson’s disease who have cognitive impairment without a dementia diagnosis
19%
Risk factors for Parkinson’s disease associated depression
Female sex
Young onset
Bradykinesia and gait abnormalities
Rapid disease progression
Cognitive impairment
Psychiatric symptoms associated with levodopa
Mania
Pathological gambling
Hypersexuality
Hallucinations
Percentage of patients with Parkinson’s disease who experience hallucinations
20%
Most common modality of hallucinations in Parkinson’s disease
Visual
Drugs most often used to treat Parkinson’s disease associated hallucinations
Low dose clozapine
Quetiapine
Drug most often used for Lewy Body Dementia, often seen with Parkinson’s disease
Rivastigmine
Pattern of dominance of Huntington’s disease
Autosomal dominant
Prevalence of psychiatric symptoms at the first presentation of Huntington’s disease
30%
Percentage of patients with Huntington’s disease where schizophreniform psychosis is the first presentation
3-6%
Increased risk of suicide among patients with Huntington’s disease compared to the general population
4x higher
Triplet repeat seen in Huntington’s disesae
CAG
Chromosome associated with Huntington’s disease
4
Number of CAG repeats where full penetrance for Huntington’s disease is seen
41
Number of CAG repeats where partial penetrance for Huntington’s disease is seen
36-40
Percentage of patients with Wilson’s disease with a psychiatric first presentation
20%
Percentage of patients with Wilson’s disease with cognitive impairment
25%
Percentage of patients with Wilson’s disease with depression
30%
Percentage of patients with Wilson’s disease with neurological involvement who have Kayser-Fleischer rings
95%
Percentage of patients with Wilson’s disease without neurological involvement who have Kayser-Fleischer rings
50-60%